Works by Qiang, Zhou


Results: 1323
    1
    2

    Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.

    Published in:
    Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-01927-9
    By:
    • Zhou, Hua-Qiang;
    • Zhang, Ya-Xiong;
    • Chen, Gang;
    • Yu, Qi-Tao;
    • Zhang, Hua;
    • Wu, Guo-Wu;
    • Wu, Di;
    • Lin, Ying-Cheng;
    • Zhu, Jun-Fei;
    • Chen, Jian-Hua;
    • Hu, Xiao-Hua;
    • Lan, Bin;
    • Zhou, Ze-Qiang;
    • Lin, Hai-Feng;
    • Wang, Zi-Bing;
    • Lei, Xiao-Lin;
    • Pan, Suo-Ming;
    • Chen, Li-Ming;
    • Zhang, Jian;
    • Kong, Tian-Dong
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50